^
Association details:
| Biomarker: | CD24 overexpression |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | remibrutinib (LOU064) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MECHANISM STUDY OF RESISTANCE TO THE TARGETED DRUG IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA
Published date:
05/14/2020
Excerpt:
We found that CD24, which was highly expressed in IBR-CLL patients may be a specific indicator and also a potential target for ibrutinib resistance in CLL (Figure D-G)...The high expression of CD24 is associated with poor prognosis of CLL patients (Figure H)...In sum, our study identifies CD24 as a novel therapeutic target for ibutinib resistance in CLL patients that indicate the prognosis.
